292 results about "Proliferative capacity" patented technology

The invention discloses a sebastes schlegeli testis cell line as well as a construction method and application thereof, and belongs to the technical field of marine fish cell culture. Primary culture and subculture are carried out on sebastes schlegeli juvenile fish testis tissues, so that the sebastes schlegeli testis cell line capable of being continuously subcultured in vitro for a long time is established. The sebastes schlegeli testis cell line established by the invention is in a fibroblast shape, has a good growth curve, and has relatively strong multiplication capacity. The lentiviral vector can significantly express the stromal cell marker gene temp2, can transfect the cell line, and can be subsequently applied to research of gonad development related functional genes. At present, the cell line has been subjected to in-vitro continuous passage for more than 60 generations, can be subjected to cryopreservation, and is high in recovery survival rate. Establishment of the cell line provides a stable and excellent experimental material for research of fish gonad development genes.

The invention provides an improved mesenchymal stem cell culture method and a culture medium used by the improved mesenchymal stem cell culture method, and belongs to the technical field of cell culture. The invention provides an improved mesenchymal stem cell culture medium. Comprising the following exogenous additive components: recombinant human serum albumin, recombinant transferrin, a recombinant human epidermal growth factor, a basic fibroblast growth factor, a platelet-derived growth factor, insulin, L-glutamine, reduced glutathione, beta-mercaptoethanol, sodium selenite, mycillin, allicin, heparin and a proliferation promoting agent. The proliferation promoting agent comprises paeoniflorin, panax notoginseng saponins, lycium barbarum polysaccharide and a snow lotus herb alcohol extract. When the culture medium is used for culturing the mesenchymal stem cells, the cell viability and multiplication capacity of the mesenchymal stem cells can be remarkably improved, the cell viability is improved by 50% or above, the cell multiplication capacity is improved by 40% or above, and the culture medium has great application potential in the aspect of culture of the mesenchymal stem cells.

The invention discloses an artificial antigen presenting cell for efficiently preparing a chimeric antigen receptor T cell (CAR-T) and a construction method of the artificial antigen presenting cell, and belongs to the field of cell therapy and immunotherapy, the artificial antigen presenting cell takes a K562 cell as a platform, an anti-CD3 single-chain antibody, an anti-CD28 single-chain antibody, a membrane binding type cell factor and a costimulatory ligand are stably expressed through genetic engineering, and the chimeric antigen receptor T cell (CAR-T) is obtained. And the local concentration of the anti-CD3 antibody is improved by adopting an HOTag3 tool. The multi-signal integration strategy obviously enhances the activation and proliferation capacity of the T cells, promotes the CAR-T cells to maintain a low differentiation state, and endows the CAR-T cells with excellent anti-tumor activity and durability. The artificial antigen presenting cell provides a novel efficient tool for the field of cellular immunotherapy, and is expected to promote development of more efficient and safer CAR-T therapy to cope with challenges of various malignant tumors.

The invention relates to the technical field of organoid culture, and discloses an organoid inverted culture device, a culture method and a pathological analysis method.The inverted culture device comprises a cell culture plate and an inverted culture small chamber, the cell culture plate comprises a plate body, and a plurality of rows of counter bores are evenly formed in the plate body; the inverted small culture chamber comprises supporting frames, a cylinder part, a supporting ring and an attachment film, the supporting ring is located above the cylinder part, the bottom end of the supporting ring is connected with the top end of the cylinder part through the three supporting frames, a through hole is formed in the center of the cylinder part, and the attachment film is arranged at the bottom end of the cylinder part; the outer diameter of the supporting ring is larger than the inner diameter of the counter bore, and the outer diameter of the cylinder part is smaller than the inner diameter of the counter bore. According to the method, the number of cells growing in a two-dimensional adherent mode in the organoid forming process can be effectively reduced, balling and growing of the organoid are facilitated, the organoid has the high multiplication capacity, and meanwhile the organoid has the immunohistochemical characteristics consistent with the tumor tissue from a patient.

The invention discloses mesenchymal stem cells, a screening and identifying method of lipoprotein particles secreted by the mesenchymal stem cells and application of the mesenchymal stem cells. The screening and identifying method of the mesenchymal stem cells comprises the steps of cell culture, genotype identification, multiplication capacity identification, pluripotency and self-renewal capacity identification, differentiation capacity identification, lipid droplet identification after high fat induction, APOE lipoprotein secretion capacity identification and the like. The screening and identifying method of the lipoprotein particles comprises the steps of high-fat-induced lipoprotein secretion, lipoprotein separation and purification, lipoprotein particle size identification, lipoprotein particle content identification and the like, and target cells and target lipoprotein particles can be rapidly and accurately screened through the systematic screening and identifying method. The screened target lipoprotein particles can improve the dyslipidemia of APOE4 / 4 genotype Alzheimer's disease. Compared with the prior art, the method not only can avoid the gene manipulation risk faced by APOE gene editing, but also can provide a new standard for identification of mesenchymal stem cells and lipoprotein particles secreted by the mesenchymal stem cells, and can screen wider and easier therapeutic cell sources for later application.

The invention discloses a detection method for rapid real-time drug effect evaluation and application of the detection method. The detection method comprises the following steps: providing a quantitative corresponding relation between a same-generation calibration change value of electrical characteristics caused by physiological changes such as cell same-representative characteristics and the like and the cell proliferation ability; adhering to-be-detected cells to the surface of the same membrane electrode; applying the medicine to be detected, and observing the same generation measurement change value of the electrical characteristics in a cell proliferation cycle; and based on the quantitative corresponding relationship, obtaining the drug effect of the corresponding real-time proliferation characteristic evaluation drug. According to the detection method provided by the invention, the physiological changes such as the same-representative characteristics of the adherent cells are monitored through the membrane electrode, and after the quantitative corresponding relation between the change indexes of the same-representative characteristics of the cells and the proliferation capacity of the cells is established, the cell proliferation capacity is detected; the change of the cell proliferation capacity can be predicted through physiological changes such as the same representative characteristics of the cells before proliferation and apoptosis of the cells, so that the judgment period of the influence of the medicine on the cells can be greatly shortened, and the progress of medicine evaluation and research and development can be remarkably accelerated.

The invention discloses a culture method of high-activity human urine-derived stem cells, which relates to the technical field of biological medicine, and is technically characterized by comprising the following steps: collecting urine samples of pregnant and lying-in women, coating a culture plate with gelatin, inducing adherence, performing passage amplification, performing immunofluorescence identification, performing function detection and other optimized conditions, and separating and culturing the stem cells. Compared with urine-derived stem cells of normal adults, the stem cells derived from pregnant women have stronger activity, higher dryness and faster multiplication capacity. The invention provides a novel and superior cell source for tissue engineering and regenerative medicine.

The invention relates to a serum-free culture medium for culturing mesenchymal stem cells as well as a preparation method and application of the serum-free culture medium. Wherein the serum-free culture medium comprises a complete culture medium and praeruptorin E, and the content of the praeruptorin E in the serum-free culture medium is 0.25-3 [mu] M. The inventor finds that a serum-free culture medium containing a certain concentration of praeruptorin E can effectively improve the decline of replicative activity of mesenchymal stem cells in in-vitro passage. Specifically, the serum-free culture medium containing the praeruptorin E with a certain concentration can reduce the expression level of a marker beta-galactosidase with reduced replicative activity in the mesenchymal stem cells with reduced replicative activity after multiple in-vitro passage, reduce the expression of a gene CDKN1A with reduced replicative activity, and increase the multiplication capacity of the mesenchymal stem cells; the mitochondrial damage is reduced.

The invention discloses an application of a circRNA molecule as a diagnostic marker in a cell senescence diagnostic kit and an application of the circRNA molecule as a cell senescence treatment target. According to the application disclosed by the invention, the circHERC1 is found to be low in expression in natural aging and aging-inducing cell models, and the circHERC1 is over-expressed in endothelial cells, so that the multiplication capacity of the endothelial cells can be improved, the telomere length of the cells can be effectively prolonged, telomerase can be activated, the positive rate of beta-galactosidase of the cells can be reduced, and the expression quantity of aging-related proteins can be reduced.

The present invention discloses a low - serum medium and its application in the preparation of cultured meat from Larimichthys crocea cells, which is also applicable to other marine or freshwater fish, belonging to the field of bioengineering technology. The low - serum medium comprises a basal medium, fetal bovine serum accounting for 30 - 80 μL / mL, and exogenous additives. The exogenous additives include human serum albumin, ascorbic acid, basic fibroblast growth factor polypeptide, human holo - transferrin, lysophosphatidic acid, and human recombinant IGF - 1. Based on the DMEM / F12 medium, the low - serum medium provided by the present invention adds six substances that promote cell growth, reduces the dependence of satellite cells on fetal bovine serum, effectively reduces the usage amount of fetal bovine serum, and saves the culture cost. Compared with the general - type medium (DMEM high - glucose, adding 10% FBS), the low - serum medium provided by the present invention has an equivalent effect on the maintenance and proliferation ability of cell stem cells.

Provided herein are methods for mechanically conditioning cells to improve their proliferative function and multipotency, as well as protect them from advancing senescence. In the methods, brachial loading alone is first used to improve the efficiency of culture expansion. Once a sufficient population of healthy cells are generated, pharmacological agents are added as a cotreatment to drive differentiation into a desired phenotype. The conditioned cells may then be used to prepare compositions for administration to a patient to treat a disease.

The invention discloses a method for wrapping stem cells by adopting programmable DNA (deoxyribonucleic acid) hydrogel and application of the method, under isothermal physiological conditions, three-dimensional DNA hydrogel is formed through a hybridization chain reaction of an initiation chain (I) and hairpin structure DNA to realize reversible wrapping and release of the stem cells. The hairpin structure DNA is formed by denaturation-renaturation treatment of at least two DNA monomer building blocks, and the mechanical rigidity of the hydrogel is realized by regulating and controlling the molar ratio of the initiation chain (I) to the total amount of the DNA monomer building blocks; the DNA hydrogel can reversibly wrap and release stem cells, and the wrapped stem cells can maintain activity and dryness and recover normal multiplication capacity after being released. According to the method disclosed by the invention, the activity and dryness of the stem cells are remarkably maintained, obvious immune activation is avoided, and the method provides a brand new tool for in-vitro culture and engineering application of the stem cells and has a wide application prospect.

The invention relates to the technical field of cell culture, and particularly provides an NK (Natural Killer) cell serum-free culture solution which is prepared from 24 percent by mass of traditional Chinese medicine extract and the balance of serum-free culture solution, the culture method of the NK cells comprises the following steps: adding the NK cells into a culture bottle, sampling and counting, diluting the cell density to 1 * 10 < 6 > / mL by using the serum-free culture solution of the NK cells, culturing in an incubator with the temperature of 37 DEG C and the CO2 content of 5% for 15 days, sampling and counting, circularly placing in a 326 mT magnetic field for 540 seconds and a 383 mT magnetic field for 120 seconds during culture, and keeping the two magnetic field environments at an interval of 0.5 hour. The serum-free culture device has a unique serum-free culture-magnetic field system, so that the multiplication capacity and killing capacity of the NK cells are not influenced or even improved while serum is not used.

The present application provides TILs comprising agents that enhance activity and / or proliferative capacity of the TILs, methods of manufacturing such TILs. and methods of using such modified TILs for enhancing an immune response.

The invention relates to a composition for promoting cell regeneration and application thereof, and particularly provides a composition for promoting cell regeneration, the composition comprises L-tryptophan oxalate, isosorbide-2-acetate and glabridin, and the composition is applied to preparation of a cell regeneration agent and construction of a cell model. The participation of the composition can effectively improve the proliferation capacity of cells and the expression level of CD63 in the cells. The method not only effectively improves the regeneration capacity of cells, but also is simple to operate and low in cost, and can be applied to the fields of preparation of cosmetics, skin care products, wound repair materials or medicines and skin repair.

The present invention provides construction and application of a novel bispecific chimeric antigen receptor (CAR), and relates to the technical field of immunotherapy. The CAR provided by the present invention comprises an antigen-binding domain, a linker peptide, a hinge region, a transmembrane domain, a 4-1BB costimulatory signaling region, and a CD3ζ signaling domain. The antigen-binding domain comprises an anti-CD 19 scFv and an anti-CD22 nano antibody, or comprises an anti-HER2 scFv and a ligand capable of identifying IGF 1R. A CAR-T provided by the present invention has the capability of simultaneously binding to two target antigens, and has stronger killer activity and cytokine release capability compared with a single-target CAR-T. A bispecific CAR-T cell provided by the present invention is a bispecific CAR-T cell based on an antiparallel β-stranded loop linker (BS Loop), and the two antigen-binding domains can both play a good role, without affecting each other, and have stronger tumor killer activity and T cell activation and proliferation capacity compared with other linear tandem bispecific CAR-T cells or reported bispecific CAR-T cells of the BS Loop.

The invention provides a mutant spinal glioma cell line. The H3K27M mutant type glioma cell line is successfully constructed, the constructed cell line has more excellent multiplication capacity, migration capacity, tumor formation capacity and drug resistance, the curative effect and potential side effects of drugs can be more comprehensively evaluated, the cell line can be used for in-vitro research on the biological function of H3K27M glioma and response to drug treatment, and the cell line can be applied to in-vitro research of the H3K27M mutant type glioma. Wide application prospects are realized.

The invention belongs to the technical field of autoimmune skin disease immunotherapy, and provides a three-target novel chimeric autoantibody receptor structure which comprises three chimeric receptors through two connecting peptides, specifically, a first chimeric autoantibody receptor comprises a Dsg1 extracellular structural domain; the second chimeric autoantibody receptor comprises a Dsg3 extracellular structural domain; the third chimeric antigen receptor comprises an extracellular domain capable of targeting a B cell associated antigen; wherein the Dsg1 extracellular structural domain is an extracellular structural domain of desmosome core glycoprotein 1; the Dsg3 extracellular structural domain is the extracellular structural domain of desmosome core glycoprotein 3. In-vitro experiments and animal experiments verify that the novel three-target CAAR-T cells can significantly increase the release of cytokines, enhance the targeted killing activity of the cytokines, and show better multiplication capacity; a novel cellular immunotherapy technology is provided for treating autoimmune skin diseases, and the application of CAAR-T in the field of autoimmune disease treatment can be expanded.

The invention provides an immortalized NK cell line SZ093 derived from healthy human umbilical cord blood as well as a preparation method and application of the immortalized NK cell line SZ093. The immortalized NK cell line SZ093 derived from the healthy human umbilical cord blood is preserved in Guangdong Microbial Culture Collection Center on September 26, 2025, and the preservation number is GDMCC No: 67036. The immortalized NK cell line SZ093 derived from the healthy human umbilical cord blood, provided by the invention, can still keep good multiplication capacity and high survival rate in a long-time (more than one year) culture process, and has high killing capacity on tumor cells.

The invention discloses a chimeric antigen receptor double-negative T cell drug co-expressing CXCR5 and IL-7 and application thereof, the cell drug can co-express CXCR5 and IL-7, and the cell drug comprises EF1-alpha, a CD8 alpha signal peptide, an NKG2D extracellular domain, a CD8 alpha hinge region, a CD8 alpha transmembrane region, a costimulatory factor 4-1BB, a CD3 zeta intracellular signal region, T2A, a chemotactic factor receptor CXCR5, P2A and interleukin IL-7 which are connected in sequence; according to the chimeric antigen receptor double-negative T cell drug co-expressing the CXCR5 and the IL-7 and the application of the chimeric antigen receptor double-negative T cell drug, the CXCR5 and the IL-7 are co-expressed on CAR-DNT cells of targeted NKG2DL, so that the migration and infiltration capacity of the drug to a tumor site is enhanced, the survival and proliferation capacity of the CAR-T cells is improved, the killing effect of the CAR-DNT cells on tumors is improved, and the drug has a good application prospect. The purpose of treating tumors is achieved, and allogenic treatment can be achieved.

The invention discloses nucleus pulposus cells as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The method comprises the steps that exosomes are collected from immortalized spherical nucleus pulposus cells and used for culturing the nucleus pulposus cells, the cultured nucleus pulposus cells have higher multiplication capacity, and large-scale in-vitro amplification of the nucleus pulposus cells is achieved; meanwhile, the cultured nucleus pulposus cells have higher extracellular matrix secretion capacity. The cultured nucleus pulposus cells are used for treating the intervertebral disc degeneration disease, the clinical use requirement can be met, and an effective treatment scheme is provided for treating the intervertebral disc degeneration disease.

The invention relates to the field of cell engineering and gene engineering, in particular to a method for enhancing the multiplication capacity of umbilical cord mesenchymal stem cells and application. The expression or activity of the STN1 gene in the umbilical cord mesenchymal stem cells is reduced through an accelerant, and the umbilical cord mesenchymal stem cells with enhanced multiplication capacity are obtained. By knocking down the hUC-MSCs of STN1, the proliferation speed of the hUC-MSCs is higher, DNA replication is more active, the clone formation ability is higher, and the aging proportion of the hUC-MSCs can be remarkably reduced.

The invention relates to the technical field of biomedicine, and provides an efficient separation and culture method of rat meniscus fibrocartilage cells. The yield and activity of the meniscus fibrocartilage cells are improved through a step-by-step enzyme digestion technology, the primary cell adherence time is shortened to 4-6 h by optimizing culture conditions, the breakthrough of sufficiently extracting the meniscus fibrocartilage cells from a single rat is achieved, the use amount of experimental animals is greatly reduced, and the cost is reduced. Meanwhile, it is ensured that the cell activity and proliferation capacity meet the requirements of subsequent passage and functional research, and the method has remarkable advantages in the aspects of ethical compliance, cost control and experimental efficiency.

The application discloses medical use of gelated cells loaded with sulfonated chitosan in treatment of atherosclerosis, and belongs to the technical field of biological medicine. The gelated cells loaded with sulfonated chitosan take macrophages as host cells, and intracellular cross-linking forms a photocrosslinking hydrogel network composed of methacrylated hyaluronic acid and sulfonated chitosan. The gelated cells completely retain cell membrane structure and membrane surface protein expression, lose the proliferation ability, and have excellent blood lipid selective adsorption capacity and foam cell lipid metabolism regulation capacity. In-vivo and in-vitro experiments prove that the gelated cells can significantly reduce blood lipid levels of atherosclerosis model animals, reduce aortic plaque area, and have good biological safety, thereby providing a new strategy and candidate drug for prevention and treatment of atherosclerosis, and having a good clinical application prospect.

To provide: a cell culture vessel that can achieve both detachability and proliferation ability, that is, can facilitate cell detachment without reducing the proliferation ability of cells; and a cell detachment method using the cell culture vessel, provided is a cell detachment method of detaching, through use of a culture vessel having a periodic recess / protrusion pattern on a culture surface, comprising a detachment step of: causing a vibrating unit in which, when an observation image of a cross section perpendicular to the culture surface is obtained, a length Lcp of a contour of the cell on the culture surface side in a measurement region of the observation image and a length Lf of the measurement region in a direction parallel to the culture surface satisfy Lcp>Lf; and transmitting the ultrasonic vibration to the cell, to thereby detach the cell from the culture surface.

The invention belongs to the technical field of biological medicines, and particularly relates to application of dirithromycin in preparation of a product for treating LINC00516 high-expression lung adenocarcinoma. The invention discloses the effect of the long-chain non-coding RNA LINC00516 in abnormal activation of the lung adenocarcinoma cell cycle for the first time. Researches show that LINC00516 is directly combined with CDK1, the kinase activity of CDK1 is remarkably enhanced, and the inhibitory phosphorylation level of CDK1 is reduced, so that lung adenocarcinoma cells are driven to quickly enter a G2 / M phase, and tumor cell proliferation is accelerated. The invention further innovatively proposes that dirithromycin is used as an intervention means, and by blocking the combination of LINC00516 and CDK1, the activity of CDK1 is effectively reduced, and the proliferation capacity of tumor cells is inhibited. In-vivo and in-vitro experiments prove that the dirithromycin can obviously inhibit the growth of lung adenocarcinoma cells with high expression of LINC00516, so that a brand-new molecular targeting treatment strategy is provided for clinic.

The present invention is directed to obtaining a cell population comprising mesenchymal stem cells that are excellent in proliferative capability and osteoblastic differentiation capability and are useful for the regeneration of periodontal tissues. The present invention is also directed to providing a cell sheet and a method for producing a cell sheet, comprising, as a material, a cell population comprising mesenchymal stem cells that are excellent in proliferative capability and osteoblastic differentiation capability and are useful for the regeneration of periodontal tissues. A cell population having alkaline phosphatase activity before calcification induction of 1 U or more is selected and obtained from a cell population comprising mesenchymal stem cells derived from a dental or periodontal tissue. A cell sheet is obtained by the following steps (a) to (c): (a) obtaining a cell population comprising mesenchymal stem cells and having alkaline phosphatase activity; (b) culturing the cell population in a calcification induction medium, and proliferating the cell population on a plastic substrate; and (c) recovering and washing a sheet-shaped cell population formed on the plastic substrate.

The process provided in this invention transfects primary cells with gene editing reagents using a high-volume gas-permeable cell culture device and a flow-through electroporation device under conditions that improve gene editing performance, cell yield, and drug (DP) quality characteristics for cell therapy applications. As demonstrated in the examples, primary cells edited according to the process provided herein achieved improved double-strand break (DSB) formation rates, increased frequency of homology-directed repair (HR) and non-homologous end joining (NHEJ) combinations, increased frequency of bi-allelic and mono-allelic HR events, improved cell viability, proliferative capacity, and cell fitness after gene editing, and reduced manufacturing time.

The invention relates to a mesenchymal stem cell serum-free culture medium with limited chemical components as well as application and a method thereof, the serum-free culture medium is completely serum-free and has definite components: all additives are known chemical substances and meet the production requirements of cGMP (Complementary Good Manufacturing Practice); telomere shortening can be obviously delayed; replicative senescence is slowed down by activating TERT expression; the multiplication capacity can also be enhanced; the P10 generation cells still have the active division capacity; multidirectional differentiation is supported; the osteogenic differentiation efficiency is superior to that of a traditional serum-containing system; and the method is suitable for industrial production and clinical transformation.